Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Risk Factors, Treatment and Outcome of 2 nd Relapse of Acute Lymphoblastic Leukemia in Children. Results of the ALL-REZ BFM Registry

Junko Yamanaka, MD, Valentijn Bon, André Schrauder, Christina Peters, MD, Günter Henze, MD, Arend von Stackelberg, MD

Blood (2012) 120 (21): 668.

https://doi.org/10.1182/blood.V120.21.668.668

Published: 2012

Journal Articles

The CD19 Antibody MOR208 Efficiently Triggers Natural Killer Cell-Mediated Cytotoxicity Against Acute Lymphoblastic Leukemia Cells From Pediatric and Adult Patients

Christian Kellner, Eugene A Zhukovsky, Monika Brüggemann, Michael Kneba, MD, PhD, André Schrauder, Martin Schrappe, Roland Repp, Andreas Humpe, Martin Gramatzki, Matthias Peipp

Blood (2012) 120 (21): 1502.

https://doi.org/10.1182/blood.V120.21.1502.1502

Published: 2012

Journal Articles

Repeated Bone Marrow Aspiration At the End of Induction Therapy: Implications for Treatment Stratification in Paediatric Acute Lymphoblastic Leukaemia

Jan Zuna, MD, PhD, Mari Arens, Rolf Koehler, PhD, Renate Panzer-Grümayer, MD, Anja Möricke, MD, Claus R Bartram, MD, Ruth Joas, Eva Fronkova, Gunnar Cario, MD, Martin Stanulla, MD, MSc, Martin Zimmermann, PhD, Jan Trka, MD, PhD, Jan Stary, M.D., Andishe Attarbaschi, MD, Georg Mann, MD, Martin Schrappe, MD, André Schrauder, MD

Blood (2011) 118 (21): 756.

https://doi.org/10.1182/blood.V118.21.756.756

Published: 2011

Journal Articles

High CD45 (PTPRC) Expression Is Associated with An Overall Poor Outcome in Childhood Acute Lymphoblastic Leukemia Treated on the ALL-BFM 2000 Protocol and Exerts An Especially Pronounced Effect in Intermediate Risk Patients

Gunnar Cario, MD, Rita Mitlohner, Martin Zimmermann, PhD, Renja Romey, Peter Rhein, PhD, André Schrauder, MD, Anja Moericke, MD, Jean-Pierre Bourquin, MD, PhD, Wolf-Dieter Ludwig, MD, Richard Ratei, MD, Martin Schrappe, MD, Leonid Karawajew, PhD, Martin Stanulla, MD, MSc

Blood (2011) 118 (21): 742.

https://doi.org/10.1182/blood.V118.21.742.742

Published: 2011

Journal Articles

Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element “Phase IB”: A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000

Anja Möricke, MD, André Schrauder, MD, Martin Zimmermann, PhD, Georg Mann, MD, Andishe Attarbaschi, MD, Rolf Koehler, PhD, Renate Panzer-Grümayer, MD, Martin Stanulla, MD, MSc, Gunnar Cario, MD, Alfred Reiter, MD, Felix Niggli, MD, Claus R Bartram, MD, Martin Schrappe, MD

Blood (2011) 118 (21): 1504.

https://doi.org/10.1182/blood.V118.21.1504.1504

Published: 2011

Journal Articles

C20orf94 deletion Is Strongly Associated with TEL/AML1 Rearrangement and Links Illegitimate V(D)J Recombination with Gender Bias In Childhood Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 1718.

https://doi.org/10.1182/blood.V116.21.1718.1718

Published: 2010

Journal Articles

Allogeneic Hematopoetic Stem Cell Transplantation (SCT) In Children with ALL: Outcome of Matched Sibling Donor SCT (MSD-SCT) Is Equivalent to Unrelated Well Matched Donor HSCT (MD-HSCT) A Report From the Prospective International Multicenter Trial ALL-SCT-BFM 2003

Blood (2010) 116 (21): 530.

https://doi.org/10.1182/blood.V116.21.530.530

Published: 2010

Journal Articles

IKZF1 Deletion Is An Independent Predictor of Outcome In Pediatric Acute Lymphoblastic Leukemia Treated According to the ALL-BFM 2000 Protocol

Petra Breithaupt, PhD, Barbara Meissner, MD, Martin Zimmermann, Anja Möricke, MD, André Schrauder, MD, Jochen Harbott, Wolf-Dieter Ludwig, MD, PhD, Rolf Köhler, PhD, Claus R Bartram, MD, Martin Schrappe, MD, Gunnar Cario, MD, Martin Stanulla, MD, MSc

Blood (2010) 116 (21): 409.

https://doi.org/10.1182/blood.V116.21.409.409

Published: 2010

Journal Articles

Prospective Evaluation of Thromboembolic Events During Chemotherapy of Childhood Acute Lymphoblastic Leukemia: Results of Randomized Trial ALL-BFM 2000.

Anja Möricke, MD, Martin Zimmermann, PhD, Jeanette Greiner, MD, André Schrauder, MD, Hansjörg Schmid, MD, Martin Stanulla, MD, Andishe Attarbaschi, MD, Alfred Reiter, MD, Georg Mann, MD, Martin Schrappe, MD

Blood (2009) 114 (22): 990.

https://doi.org/10.1182/blood.V114.22.990.990

Published: 2009

Journal Articles

Significant Reduction of Treatment Related Mortality after Stem Cell Transplantation in 647 Children and Adolescents with ALL within BFM Trials during the Last 12 Years: A Long Term Analysis from 1996 to 2007

André Schrauder, Martin Schrappe, Arend Stackelberg, Peter Bader, Wolfgang Holter, Rupert Handgretinger, Wolfram Ebell, Dagmar Dilloo, Tayfun Güngör, Monika Fuehrer, Hartmut Kabisch, Martin Zimmermann, Ulrike Poetschger, Karl-Walter Sykora, Christina Peters

Blood (2008) 112 (11): 567.

https://doi.org/10.1182/blood.V112.11.567.567

Published: 2008

Journal Articles

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) Treated in the AIEOP-BFM ALL 2000 Study.

Andrea Biondi, André Schrauder, Maria Grazia Valsecchi, Claus R Bartram, Georg Mann, Giulio De Rossi, Anja Möricke, Rosanna Parasole, Jochen Harbott, Chiara Messina, C. Rizzari, Giuseppe Masera, Martin Schrappe

Blood (2008) 112 (11): 1511.

https://doi.org/10.1182/blood.V112.11.1511.1511

Published: 2008

Journal Articles

Childhood Acute Lymphoblastic Leukemia: High Genomic Stability from Initial Diagnosis to Early Relapse.

Barbara Meissner, MD, Cornelia Eckert, PhD, Anja Moericke, MD, Arend von Stackelberg, MD, Renate Kirschner-Schwabe, PhD, Gunnar Cario, MD, André Schrauder, MD, Martin Zimmermann, PhD, Karl Welte, MD, Martin Schrappe, MD, Martin Stanulla, MD, MSc

Blood (2008) 112 (11): 1522.

https://doi.org/10.1182/blood.V112.11.1522.1522

Published: 2008

Journal Articles

Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000)

Martin Schrappe, MD, Martin Zimmermann, PhD, Anja Möricke, MD, Georg Mann, MD, Maria Grazia Valsecchi, PhD, Claus R Bartram, MD, Andrea Biondi, MD, Renate Panzer-Grümayer, MD, André Schrauder, MD, Franco Locatelli, MD, Alfred Reiter, MD, Giuseppe Basso, MD, Felix Niggli, MD, Maurizio Aricò, MD, Valentino Conter, MD

Blood (2008) 112 (11): 7.

https://doi.org/10.1182/blood.V112.11.7.7

Published: 2008

Journal Articles

Relapse in Childhood “Very High Risk” Acute Lymphoblastic Leukemia Treated with BFM Chemotherapy Has a Dismal Outcome Even When Treated with Transplantation.

Adriana Balduzzi, MD, Maria Grazia Valsecchi, PhD, André Schrauder, MD, Daniela Silvestri, MSc, Barbara Buldini, MD, Arend von Stackelberg, MD, Anna Maria Testi, MD, Thomas Klingebiel, MD, Christina Peters, MD, Carmelo Rizzari, MD, Elena Barisone, MD, Martin Schrappe, MD

Blood (2008) 112 (11): 915.

https://doi.org/10.1182/blood.V112.11.915.915

Published: 2008

Journal Articles

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Blood (2007) 110 (11): 1425.

https://doi.org/10.1182/blood.V110.11.1425.1425

Published: 2007

Journal Articles

Prospective Evaluation of MRD-Kinetics in 274 Children with High-Risk ALL Treated in Trial ALL-BFM 2000: Insights into Development of Resistance and Impact on Further Refinement of Treatment Stratification Strategies.

André Schrauder, MD, Martin Stanulla, MD, Thomas Flohr, PhD, Gunnar Cario, MD, Rolf Köhler, PhD, Renate Panzer-Grümayer, MD, Beat Schäfer, PhD, Martin Zimmermann, PhD, Christina Peters, MD, Claus R. Bartram, MD, Martin Schrappe, MD

Blood (2007) 110 (11): 585.

https://doi.org/10.1182/blood.V110.11.585.585

Published: 2007

Journal Articles

Time to Leukaemia (TTL) Assessed in NOD/SCID Mice Transplanted with Primary ALL Leukaemia Cells Determines Early Relapse in Patients and Is Identified by a Specific Gene Signature.

Lüder H. Meyer, MD, Sarah M. Eckhoff, MD, Manon Dammé, Martin Zimmermann, PhD, André Schrauder, MD, Georgia Lahr, PhD, Karsten Stahnke, MD, Martin Schrappe, MD, Klaus M. Debatin, MD

Blood (2007) 110 (11): 726.

https://doi.org/10.1182/blood.V110.11.726.726

Published: 2007

Journal Articles

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Acute Lymphoblastic Leukemia (ALL) According to WBC Count, Age and TEL/AML1 Status at Diagnosis. Results of the AIEOP-BFM ALL 2000 Study.

Valentino Conter, MD, André Schrauder, MD, Helmut Gadner, MD, Maria Grazia Valsecchi, PhD, Martin Zimmermann, PhD, Michael Dvorzak, MD, Andrea Biondi, MD, Claus R. Bartram, PhD, Giuseppe Basso, MD, Martin Stanulla, MD, Maurizio Aricò, MD, Karl Welte, MD, Giuseppe Masera, MD, Martin Schrappe, MD

Blood (2007) 110 (11): 544.

https://doi.org/10.1182/blood.V110.11.544.544

Published: 2007

Journal Articles

The Importance of Harmonizing Transplantation Procedures in Children with ALL: ALL-SCT-BFM 2003, a Prospective Multicenter Trial.

André Schrauder, MD, Arend Stackelberg, MD, Martin Schrappe, MD, Thomas Klingebiel, MD, Wolfgang Holter, MD, Karl-Walter Sykora, MD, Rupert Handgretinger, MD, Wolfram Ebell, MD, Ulrike Pötschger, PhD, Martin Zimmermann, PhD, Susanne Karlhuber, PhD, Christina Peters, MD

Blood (2007) 110 (11): 1099.

https://doi.org/10.1182/blood.V110.11.1099.1099

Published: 2007

Journal Articles

Childhood Secondary ALL after ALL Treatment.

Jan Zuna, Cornelia Eckert, Hélène Cavé, Claus Meyer, Björn Schneider, Eva Fronkova, Katerina Muzikova, Denisa Mendelova, Patrick Boutard, André Schrauder, Jaroslav Sterba, Rolf Marschalek, Jan Stary, Jan Trka

Blood (2005) 106 (11): 852.

https://doi.org/10.1182/blood.V106.11.852.852

Published: 2005

NARROW

Risk Factors, Treatment and Outcome of 2 nd Relapse of Acute Lymphoblastic Leukemia in Children. Results of the ALL-REZ BFM Registry

The CD19 Antibody MOR208 Efficiently Triggers Natural Killer Cell-Mediated Cytotoxicity Against Acute Lymphoblastic Leukemia Cells From Pediatric and Adult Patients

Repeated Bone Marrow Aspiration At the End of Induction Therapy: Implications for Treatment Stratification in Paediatric Acute Lymphoblastic Leukaemia

High CD45 (PTPRC) Expression Is Associated with An Overall Poor Outcome in Childhood Acute Lymphoblastic Leukemia Treated on the ALL-BFM 2000 Protocol and Exerts An Especially Pronounced Effect in Intermediate Risk Patients

Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element “Phase IB”: A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000

C20orf94 deletion Is Strongly Associated with TEL/AML1 Rearrangement and Links Illegitimate V(D)J Recombination with Gender Bias In Childhood Acute Lymphoblastic Leukemia

Allogeneic Hematopoetic Stem Cell Transplantation (SCT) In Children with ALL: Outcome of Matched Sibling Donor SCT (MSD-SCT) Is Equivalent to Unrelated Well Matched Donor HSCT (MD-HSCT) A Report From the Prospective International Multicenter Trial ALL-SCT-BFM 2003

IKZF1 Deletion Is An Independent Predictor of Outcome In Pediatric Acute Lymphoblastic Leukemia Treated According to the ALL-BFM 2000 Protocol

Prospective Evaluation of Thromboembolic Events During Chemotherapy of Childhood Acute Lymphoblastic Leukemia: Results of Randomized Trial ALL-BFM 2000.

Significant Reduction of Treatment Related Mortality after Stem Cell Transplantation in 647 Children and Adolescents with ALL within BFM Trials during the Last 12 Years: A Long Term Analysis from 1996 to 2007

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) Treated in the AIEOP-BFM ALL 2000 Study.

Childhood Acute Lymphoblastic Leukemia: High Genomic Stability from Initial Diagnosis to Early Relapse.

Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000)

Relapse in Childhood “Very High Risk” Acute Lymphoblastic Leukemia Treated with BFM Chemotherapy Has a Dismal Outcome Even When Treated with Transplantation.

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Prospective Evaluation of MRD-Kinetics in 274 Children with High-Risk ALL Treated in Trial ALL-BFM 2000: Insights into Development of Resistance and Impact on Further Refinement of Treatment Stratification Strategies.

Time to Leukaemia (TTL) Assessed in NOD/SCID Mice Transplanted with Primary ALL Leukaemia Cells Determines Early Relapse in Patients and Is Identified by a Specific Gene Signature.

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Acute Lymphoblastic Leukemia (ALL) According to WBC Count, Age and TEL/AML1 Status at Diagnosis. Results of the AIEOP-BFM ALL 2000 Study.

The Importance of Harmonizing Transplantation Procedures in Children with ALL: ALL-SCT-BFM 2003, a Prospective Multicenter Trial.

Childhood Secondary ALL after ALL Treatment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only